A Sanofi alum looks to take on the TL1A field with $165M for Bionyranews2026-06-22T11:00:47+00:00June 22nd, 2026|Endpoints News|
Treasury weighs screening investments in China biotechnews2026-06-18T16:47:52+00:00June 18th, 2026|Endpoints News|
UCSF spinout Kopra Bio raises $9.1M to test virus therapy in brain cancernews2026-06-16T10:45:36+00:00June 16th, 2026|Endpoints News|
WuXi AppTec sues Pentagon in challenge over inclusion on Chinese military listnews2026-06-12T11:21:11+00:00June 12th, 2026|Endpoints News|
Sciwind has two Western partners for its obesity drug, but is open to morenews2026-06-12T09:00:41+00:00June 12th, 2026|Endpoints News|
WuXi AppTec added to Pentagon’s list of companies linked to Chinese military news2026-06-09T11:12:47+00:00June 9th, 2026|Endpoints News|
In Washington, biotech’s China hawks are winning the conversationnews2026-06-05T18:37:56+00:00June 5th, 2026|Endpoints News|
Travere pays Everest $112M upfront to grow rare kidney disease pipelinenews2026-06-02T13:55:55+00:00June 2nd, 2026|Endpoints News|
Citing ‘dangerous deals,’ lawmakers propose China restrictionsnews2026-06-02T12:00:58+00:00June 2nd, 2026|Endpoints News|
After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listingnews2026-06-01T14:11:13+00:00June 1st, 2026|Endpoints News|
